Groovy Medicine secures tens of millions in strategic funding round

Recently, Groovy Medicine announced the completion of a strategic financing round totaling tens of millions of Chinese yuan. This round was led by Xinghua Dingli Capital, with participation from the Hangzhou STI Group Disruptive Technology Achievement Transformation Fund and the Hangzhou Talent Fund.

The proceeds will be used to advance the clinical trials of the GW-01 pipeline and accelerate the discovery of additional innovative targets on the Groovy platform, as well as to foster external collaborations.

According to its official website, Groovy Medicine was established in November 2022 and is headquartered in the Digital & Health Industry Park of Hangzhou Future Sci-Tech City, Zhejiang Province. The company is a future-oriented computing-driven drug discovery enterprise. Leveraging the rich innovative ecosystem of Westlake University and Westlake Laboratory, Groovy Medicine has assembled an R&D team with profound expertise and strong technical capabilities.

The founder, Professor Li Xu, brings extensive research experience and exceptional innovative vision. The core team, which includes graduates from top-tier universities like Tsinghua University and Peking University, possesses substantial experience in domestic and international drug development, with a proven track record of advancing multiple drug candidates from target discovery to clinical stages.

Professor Li stated, "We sincerely appreciate our new and existing investors for their recognition and support. Leveraging our proprietary high-dimensional biology platform, we have established a portfolio of multiple innovative pipelines with first-in-class potential. Among them, the core asset, GW-01, has essentially completed its IND-enabling studies and is expected to soon enter the clinical trial stage. Since inception, Groovy Medicine has assembled a professional, efficient, and cohesive R&D and operations team. Our platform's value and pipeline progress have garnered significant attention from pharmaceutical companies both domestically and internationally. By continuously integrating cutting-edge resources and pooling industry expertise, we are committed to enhancing the precision and efficiency of target discovery, thereby injecting new vitality into traditional drug development paradigms."

He Jiongling, Investment Director of Xinghua Dingli, commented, "We firmly believe that innovative drug discovery driven by data and algorithms is a pivotal force in breaking through traditional R&D bottlenecks and leading the transformation of the pharmaceutical industry. The Groovy Medicine team possesses not only profound insights into complex biology but has also established a unique and robust foundational infrastructure comprising proprietary data assets and algorithmic models. They are dedicated to revolutionizing the drug discovery paradigm from its very foundation. We see immense potential for them to grow into a next-generation biotech platform company and look forward to working together to bring breakthrough therapies to patients worldwide."